{"id":23057,"date":"2026-04-09T13:45:59","date_gmt":"2026-04-09T00:45:59","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=23057"},"modified":"2026-04-09T13:45:59","modified_gmt":"2026-04-09T00:45:59","slug":"pharmac-decision-to-fund-two-treatment-combinations-and-widen-access-to-ibrutinib-for-cll","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=23057","title":{"rendered":"Pharmac decision to fund two treatment combinations and widen access to ibrutinib for CLL"},"content":{"rendered":"<p>We are very pleased to announce that<strong> Pharmac has announced new funded treatment options for people with chronic lymphocytic leukaemia (CLL).<\/strong><\/p>\n<p>From <strong>1 May 2026<\/strong>, two fixed\u2011duration combination therapies, venetoclax + ibrutinib and venetoclax + obinutuzumab,\u00a0will be funded as first\u2011line treatments.<\/p>\n<p>Access to ibrutinib <span data-olk-copy-source=\"MessageBody\">monotherapy<\/span> is also being widened so it can be used as a second\u2011line option for anyone whose CLL has relapsed or caused intolerable side effects.<\/p>\n<p>These changes will give more people access to modern, effective treatments and reduce pressure on hospital infusion services.<\/p>\n<p>Pharmac has also updated criteria so people currently self\u2011funding can transition to funded treatment within six months.<\/p>\n<p>\u2764\ufe0f We\u2019re grateful to our members who have shared their stories, your voices, alongside the work of the CLLANZ Trust, have helped influence better options and outcomes<em class=\"html-em xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x1hl2dhg x16tdsg8 x1vvkbs\">.<\/em><\/p>\n<div>Please click<a href=\"https:\/\/www.beehive.govt.nz\/release\/pharmac-update-blood-cancer-decision-due-patient-feedback?fbclid=IwY2xjawRD1YJleHRuA2FlbQIxMABicmlkETFEUHNlTFF3RVVJbUh2VE1zc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHqUt8QbDvcZQZOB9eOB6x4m2W5z-1ttyik_enNLu3sNJg5hLBX9ephR9jsGA_aem_jsC-c0ojHXbXhDgaXr1-Hw\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #3366ff;\"><strong> here<\/strong><\/span><\/a> for an official announcement from the Honourable David Seymour.<\/div>\n","protected":false},"excerpt":{"rendered":"<p>We are very pleased to announce that Pharmac has announced new funded treatment options for people with chronic lymphocytic leukaemia [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":23058,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,17],"tags":[38,79,82,95,98,102,105,111,155],"class_list":["post-23057","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","category-featured","tag-pharmac","tag-sam-neil-blood-cancer-pharmac","tag-rachel-smalley","tag-ben-schrader-cll-advocates-chronic-lymphocyctic-leukaemia","tag-valuing-life-new-zealand-medicine-access-summit","tag-david-seymour-christopher-luxon","tag-dr-malcolm-mulholland","tag-leukaemia-and-blood-cancer-new-zealand","tag-venetoclax-ibrutinib"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2026\/04\/Pharmac-image.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/23057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23057"}],"version-history":[{"count":3,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/23057\/revisions"}],"predecessor-version":[{"id":23064,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/23057\/revisions\/23064"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/23058"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}